Publications & Reports

Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.

Birch CJ, Tyssen DP, Tachedjian G, Doherty R, Hayes K, Mijch A, Lucas CR
Virology Department, Macfarlane Burnet Centre for Medical Research, Fairfield Hospital, Australia.


Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha. Complete healing of lesions occurred in 1 patient; a second had significant regression of the infected area. In the third, the lesion was stabilized twice after application of the preparation and reduced in size after a subsequent treatment. In vitro studies confirmed that isolates from these patients were acyclovir- or acyclovir/foscarnet-resistant. In addition, they revealed strong synergy between TFT and interferon-alpha for these isolates and for strains with wild-type drug sensitivity profiles. Topical TFT/interferon-alpha may be of benefit in the therapy of mucocutaneous HSV infections, especially when they are resistant to treatment with systemic antiviral agents.


  • Journal: The Journal of Infectious Diseases
  • Published: 01/07/1992
  • Volume: 166
  • Issue: 1
  • Pagination: 108-112